CN101636165A - 用睾酮和孕激素治疗干眼症 - Google Patents

用睾酮和孕激素治疗干眼症 Download PDF

Info

Publication number
CN101636165A
CN101636165A CN200780049245A CN200780049245A CN101636165A CN 101636165 A CN101636165 A CN 101636165A CN 200780049245 A CN200780049245 A CN 200780049245A CN 200780049245 A CN200780049245 A CN 200780049245A CN 101636165 A CN101636165 A CN 101636165A
Authority
CN
China
Prior art keywords
composition
testosterone
progestin
concentration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780049245A
Other languages
English (en)
Chinese (zh)
Inventor
C·G·康纳
C·海纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern College of Optometry
Original Assignee
Southern College of Optometry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern College of Optometry filed Critical Southern College of Optometry
Publication of CN101636165A publication Critical patent/CN101636165A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Eyeglasses (AREA)
CN200780049245A 2006-12-05 2007-12-05 用睾酮和孕激素治疗干眼症 Pending CN101636165A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,347 2006-12-05
US11/634,347 US20080132475A1 (en) 2006-12-05 2006-12-05 Treatment for dry eye

Publications (1)

Publication Number Publication Date
CN101636165A true CN101636165A (zh) 2010-01-27

Family

ID=39476533

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780049245A Pending CN101636165A (zh) 2006-12-05 2007-12-05 用睾酮和孕激素治疗干眼症
CN200780049235A Pending CN101636164A (zh) 2006-12-05 2007-12-05 干眼症的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200780049235A Pending CN101636164A (zh) 2006-12-05 2007-12-05 干眼症的治疗

Country Status (12)

Country Link
US (3) US20080132475A1 (https=)
EP (2) EP2101785A4 (https=)
JP (2) JP2010511729A (https=)
KR (2) KR20090104814A (https=)
CN (2) CN101636165A (https=)
AU (1) AU2009202711A1 (https=)
BR (2) BRPI0720172A2 (https=)
CA (2) CA2671698A1 (https=)
EA (2) EA200900663A1 (https=)
IL (1) IL199094A0 (https=)
MX (2) MX2009005993A (https=)
WO (2) WO2008070728A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188708A (zh) * 2013-03-15 2015-12-23 格利亚有限责任公司 颅部的药物递送
CN109700763A (zh) * 2011-01-26 2019-05-03 阿勒根公司 用于治疗眼科病症的雄性激素组合物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
EP2320912B1 (en) * 2008-08-05 2015-01-14 University College Cork-National University of Ireland, Cork Treatment of retinal degeneration
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2877184T (pt) * 2012-07-27 2019-12-02 Glia Llc Composições e tratamento para doenças e distúrbios oculares
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
SG10202011669PA (en) * 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
WO2016159350A1 (ja) * 2015-04-03 2016-10-06 参天製薬株式会社 ナンドロロンまたはそのエステル、メテノロンまたはそのエステルを有効成分とするドライアイ治療剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN110072523A (zh) 2016-09-07 2019-07-30 格利亚有限责任公司 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状
TW202131927A (zh) * 2019-11-13 2021-09-01 美商葛莉亞有限責任公司 睾固酮組合物
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS59184135A (ja) * 1983-04-04 1984-10-19 Teijin Ltd グリセリンピログルタミン酸エステル類を含有する医薬品組成物
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
EP1806131A3 (en) * 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
WO1998037871A1 (en) * 1997-02-28 1998-09-03 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of testosterone
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2774587B1 (fr) * 1998-02-09 2000-03-10 Oreal Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
US6569903B2 (en) * 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US6630175B1 (en) * 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
WO2004045510A2 (en) * 2002-11-15 2004-06-03 Panaseca, Inc. Methods and compositions for alleviating dry eyes
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7960350B2 (en) * 2003-10-24 2011-06-14 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109700763A (zh) * 2011-01-26 2019-05-03 阿勒根公司 用于治疗眼科病症的雄性激素组合物
CN105188708A (zh) * 2013-03-15 2015-12-23 格利亚有限责任公司 颅部的药物递送
CN105188708B (zh) * 2013-03-15 2019-06-28 格利亚有限责任公司 颅部的药物递送

Also Published As

Publication number Publication date
IL199094A0 (en) 2010-03-28
CN101636164A (zh) 2010-01-27
JP2010511730A (ja) 2010-04-15
CA2671698A1 (en) 2008-06-12
WO2008070726A3 (en) 2008-08-21
BRPI0720172A2 (pt) 2014-01-07
EP2124958A2 (en) 2009-12-02
WO2008070726A2 (en) 2008-06-12
EP2101785A4 (en) 2009-12-30
MX2009005993A (es) 2009-12-14
EP2124958A4 (en) 2009-12-30
EP2101785A2 (en) 2009-09-23
CA2671769A1 (en) 2008-06-12
WO2008070728A2 (en) 2008-06-12
AU2009202711A1 (en) 2009-07-23
KR20090104813A (ko) 2009-10-06
EA200900662A1 (ru) 2009-12-30
KR20090104814A (ko) 2009-10-06
US20080132475A1 (en) 2008-06-05
JP2010511729A (ja) 2010-04-15
WO2008070728A3 (en) 2008-08-07
MX2009005994A (es) 2009-12-14
US20210008079A1 (en) 2021-01-14
US20140113889A1 (en) 2014-04-24
EA200900663A1 (ru) 2009-12-30
BRPI0719918A2 (pt) 2014-03-04

Similar Documents

Publication Publication Date Title
CN101636165A (zh) 用睾酮和孕激素治疗干眼症
US20100016264A1 (en) Treatment for dry eye using testosterone and progestagen
TWI335819B (en) Use of oculosurface selective glucocorticoid in the treatment of dry eye
KR101928321B1 (ko) 프로게스틴/에스트라디올 경피 젤
JP6296977B2 (ja) 経皮薬物送達システムおよびその使用方法
Samsioe Transdermal hormone therapy: gels and patches
MX2008001687A (es) Composiciones de estrogenos y metodos terapeuticos de uso.
Murray Natural progesterone: what role in women’s health care
US20130184245A1 (en) Endometriosis treatment
US20180263901A1 (en) Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
AU2006218654A1 (en) Combination therapy for topical application
US20200383906A1 (en) Hormonal contraception using a vaginal ring which releases estriol and trimegestone
DE102004023984A1 (de) Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060211660A1 (en) Combination therapy for topical application in the treatment of dry eye syndrome
Moghadam et al. Advances in menopausal hormonal therapy delivery systems: a comparative review
HK40031764B (zh) 用於治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
TW201416076A (zh) 用於眼部疾病或異常之組合物及其治療方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100127